ConductScience.org, home

Paper26317305

Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer.

Phillips T and 6 others. Appl Immunohistochem Mol Morphol, 2015. Cited by 155 papers, by iCite.

Cite this record

ConductScience Library. Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer. Papers, record 26317305. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26317305

Download JSON
Disease
urinary bladder cancer87 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer.
PubMed
Journal
Appl Immunohistochem Mol Morphol
PubMed
Year
2015
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
155
iCite
Relative citation ratio, by iCite
4.3
iCite
Revised in PubMed
2022-04-08
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Phillips TTherese
2Simmons PPauline
3Inzunza HDHector D
4Cogswell JJohn
5Novotny J JrJames
6Taylor CClive
7Zhang XXiaoling

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AutomationMajor topic
B7-H1 AntigenMajor topic
Carcinoma, Non-Small-Cell LungMajor topic
Lung NeoplasmsMajor topic
Antibodies, Monoclonal
Cell Line, Tumor
Gene Knockdown Techniques
Humans
Immunohistochemistry

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT04186013Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncerResults

Source ClinicalTrials.gov

Download CSV of trials

References15

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
112091876Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.Nat Med2002https://conductscience.org/library/papers/12091876PubMed
212538684Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.J Immunol2003https://conductscience.org/library/papers/12538684PubMed
321179091A TALE nuclease architecture for efficient genome editing.Nat Biotechnol2011https://conductscience.org/library/papers/21179091PubMed
420373055High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation.Med Oncol2011https://conductscience.org/library/papers/20373055PubMed
522658127Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.N Engl J Med2012https://conductscience.org/library/papers/22658127PubMed
623389362Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study.Tumori2012https://conductscience.org/library/papers/23389362PubMed
722868219Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung.Clin Lung Cancer2013https://conductscience.org/library/papers/22868219PubMed
824217091Programmed death ligand-1 expression in non-small cell lung cancer.Lab Invest2014https://conductscience.org/library/papers/24217091PubMed
924714771Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.Clin Cancer Res2014https://conductscience.org/library/papers/24714771PubMed
1025399552Nivolumab in previously untreated melanoma without BRAF mutation.N Engl J Med2015https://conductscience.org/library/papers/25399552PubMed
1125704439Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.Lancet Oncol2015https://conductscience.org/library/papers/25704439PubMed
1210581077B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion.Nat Med1999https://conductscience.org/library/papers/10581077PubMed
1311015443Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.J Exp Med2000https://conductscience.org/library/papers/11015443PubMed
1425795410Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.Lancet Oncol2015https://conductscience.org/library/papers/25795410PubMed
1515297412B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression.Clin Cancer Res2004https://conductscience.org/library/papers/15297412PubMed

Download CSV of references

Cited by97

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 155 citations.

PMIDTitleJournalYearIn PapersSource
42568819Biomarkers for predicting and monitoring the efficacy of cancer vaccines.Front Oncol2026https://conductscience.org/library/papers/42568819PubMed
41702354Fast Real-Time Assessment of Combination Therapies in Immuno-ONcology in patients with advanced non-small-cell lung cancer (FRACTION-Lung).ESMO Open2026https://conductscience.org/library/papers/41702354PubMed
41590351Machine Learning in Biomarker-Driven Precision Oncology: Automated Immunohistochemistry Scoring and Emerging Directions in Genitourinary Cancers.Curr Oncol2026https://conductscience.org/library/papers/41590351PubMed
41415556Unraveling the complexity of PD-L1 assays: a descriptive review of the methodology, scoring, and practical implications.Front Oncol2025https://conductscience.org/library/papers/41415556PubMed
40991883Clinical Interchangeability of PD-L1 Immunohistochemistry Assays in First-Line Non-Small Cell Lung Cancer Management With Cemiplimab.JCO Precis Oncol2025https://conductscience.org/library/papers/40991883PubMed
40775055Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial.Nat Med2025https://conductscience.org/library/papers/40775055PubMed
40514707Myomedin variants developed for in vitro PD-L1 diagnostics in tissue samples of non-small cell lung carcinoma patients.J Transl Med2025https://conductscience.org/library/papers/40514707PubMed
39074963Exploring markers of immunoresponsiveness in papillary thyroid carcinoma and future treatment strategies.J Immunother Cancer2024https://conductscience.org/library/papers/39074963PubMed
38927511Nearly Half of Patients with Anaplastic Thyroid Cancer May Be Amenable to Immunotherapy.Biomedicines2024https://conductscience.org/library/papers/38927511PubMed
38496691Immunotherapy for advanced non-small cell lung cancer with negative programmed death-ligand 1 expression: a literature review.Transl Lung Cancer Res2024https://conductscience.org/library/papers/38496691PubMed
37745839Role of immunotherapy in chondrosarcoma: A case report and review of the literature.Ther Adv Med Oncol2023https://conductscience.org/library/papers/37745839PubMed
37510761Novel Biomarkers of Gastric Cancer: Current Research and Future Perspectives.J Clin Med2023https://conductscience.org/library/papers/37510761PubMed
36892210Comparative evaluation of PD-L1 expression in cytology imprints, circulating tumour cells and tumour tissue in non-small cell lung cancer patients.Mol Oncol2023https://conductscience.org/library/papers/36892210PubMed
36334214Predictive performance of PD-L1 tumor proportion score for nivolumab response evaluated using archived specimens in patients with non-small cell lung cancer experiencing a postoperative recurrence.Invest New Drugs2023https://conductscience.org/library/papers/36334214PubMed
36309362Clinicopathological and Prognostic Significance of Programmed Death Ligand-1 SP142 Expression in 132 Patients With Triple-negative Breast Cancer.In Vivo2022https://conductscience.org/library/papers/36309362PubMed
36190525A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412.Clin Cancer Res2022https://conductscience.org/library/papers/36190525PubMed
36171566The expression profiles of CD47 in the tumor microenvironment of salivary gland cancers: a next step in histology-driven immunotherapy.BMC Cancer2022https://conductscience.org/library/papers/36171566PubMed
35840720Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab ± ipilimumab.Mod Pathol2022https://conductscience.org/library/papers/35840720PubMed
35327345Gastric Cancer: Mechanisms, Biomarkers, and Therapeutic Approaches.Biomedicines2022https://conductscience.org/library/papers/35327345PubMed
35116387Clinicopathological implications of lncRNAs, immunotherapy and DNA methylation in lung squamous cell carcinoma: a narrative review.Transl Cancer Res2021https://conductscience.org/library/papers/35116387PubMed

See all 97 cited byDownload CSV of cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
KRT183875PubTator's text mininghttps://conductscience.org/library/genes/3875NCBI Gene
KRT83856PubTator's text mininghttps://conductscience.org/library/genes/3856NCBI Gene
PDCD15133PubTator's text mininghttps://conductscience.org/library/genes/5133NCBI Gene

Download CSV of genes

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
ATEZOLIZUMABCHEMBL3707227Results1https://conductscience.org/library/drugs/CHEMBL3707227

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/26317305

GET https://conductscience.org/api/papers/v1/26317305/cited_by?page=2